Drugs

, Volume 62, Issue 4, pp 605–616 | Cite as

Drugs Affecting Homocysteine Metabolism

Impact on Cardiovascular Risk
  • Cyrus Desouza
  • Maty Keebler
  • Dennis B. McNamara
  • Vivian Fonseca
Review Article

Abstract

Elevated total plasma homocysteine has been established as an independent risk factor for thrombosis and cardiovascular disease. A strong relationship between plasma homocysteine levels and mortality has been reported in patients with angiographically confirmed coronary artery disease.

Homocysteine is a thiol containing amino acid. It can be metabolised by different pathways, requiring various enzymes such as cystathionine β-synthase and methylenetetrahydrofolate reductase. These reactions also require several co-factors such as vitamin B6 and folate. Medications may interfere with these pathways leading to an alteration of plasma homocysteine levels.

Several drugs have been shown to effect homocysteine levels. Some drugs frequently used in patients at risk of cardiovascular disease, such as the fibric acid derivatives used in certain dyslipidaemias and metformin in type 2 (non-insulin-dependent) diabetes mellitus, also raise plasma homocysteine levels. This elevation poses a theoretical risk of negating some of the benefits of these drugs.

The mechanisms by which drugs alter plasma homocysteine levels vary. Drugs such as cholestyramine and metformin interfere with vitamin absorption from the gut. Interference with folate and homocysteine metabolism by methotrexate, nicotinic acid (niacin) and fibric acid derivatives, may lead to increased plasma homocysteine levels.

Treatment with folate or vitamins B6 and B12 lowers plasma homocysteine levels effectively and is relatively inexpensive. Although it still remains to be demonstrated that lowering plasma homocysteine levels reduces cardiovascular morbidity, surrogate markers for cardiovascular disease have been shown to improve with treatment of hyperhomocystenaemia. Would drugs like metformin, fibric acid derivatives and nicotinic acid be more effective in lowering cardiovascular morbidity and mortality, if the accompanying hyperhomocysteinaemia is treated? The purpose of this review is to highlight the importance of homocysteine as a risk factor, and examine the role and implications of drug induced modulation of homocysteine metabolism.

References

  1. 1.
    Eikelboom JW, Lonn E, Genest J, et al. Homocysteine and cardiovascular disease: a critical review of the epidemiological evidence. Ann Intern Med 1999; 131(5): 363–75PubMedGoogle Scholar
  2. 2.
    Niranjan S, Killian R. Risk factor modification for cardiac disease: homocysteine, B-vitamins, and coronary artery disease. Med Clin North Am 2000; 84(1): 215–37CrossRefGoogle Scholar
  3. 3.
    Refsum H, Ueland PM, Nygard O, et al. Homocysteine and cardiovascular disease. Annu Rev Med 1998; 49: 31–62PubMedCrossRefGoogle Scholar
  4. 4.
    Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary arteriosclerosis. J Am Coll Cardiol 1996; 27: 517–27PubMedCrossRefGoogle Scholar
  5. 5.
    Fonseca V, Guba SC, Fink LM. Hyperhomocystenemia and the endocrine system: implications for atherosclerosis and thrombosis. Endocr Rev 1999; 20(5): 738–59PubMedCrossRefGoogle Scholar
  6. 6.
    Boers GH, Smals AG, Trijbels F, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985; 313: 709–15PubMedCrossRefGoogle Scholar
  7. 7.
    Bostom AG, Jacques PF, Nadeau MR, et al. Post-methionine load hyperhomocystenemia in persons with normal fasting total plasma homocysteine: the NHLBI family heart study. Atherosclerosis 1995; 116: 147–51PubMedCrossRefGoogle Scholar
  8. 8.
    Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049–57PubMedCrossRefGoogle Scholar
  9. 9.
    Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine concentration and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230–6PubMedCrossRefGoogle Scholar
  10. 10.
    Omland T, Samuelsson A, Hartford M, et al. Serum homocysteine concentration as an indicator of survival in patients with acute coronary syndromes. Arch Intern Med 2000; 160:1834–40PubMedCrossRefGoogle Scholar
  11. 11.
    Selhub J, Jacques PR, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332: 286–91PubMedCrossRefGoogle Scholar
  12. 12.
    Aronow WS, Ahn C, Schoenfeld MR. Association between plasma homocysteine and extracranial carotid arterial disease in older persons. Am J Cardiol 1997; 79: 1432–3PubMedCrossRefGoogle Scholar
  13. 13.
    Konecky N, Malinow MR, Tunick PA, et al. Correlation between plasma homocyst(e)ine and aortic atherosclerosis. Am Heart J 1997; 133: 534–40PubMedCrossRefGoogle Scholar
  14. 14.
    Bots ML, Launer LJ, Lindemans J, et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam study. Arch Intern Med 1999; 159:38–44PubMedCrossRefGoogle Scholar
  15. 15.
    Dierkes J, Westphal S, Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate [abstract]. Lancet 1999; 354: 219–20PubMedCrossRefGoogle Scholar
  16. 16.
    De Logeril M, Salen O, Paillard F, et al. Lipid-lowering drugs and homocysteine [abstract]. Lancet 1999; 353: 209–10CrossRefGoogle Scholar
  17. 17.
    Rubins HB, Robins SJ, Collins D, et al. Gemfibrosal for the secondary prevention of coronary heart disease in men with low concentration of HDL cholesterol. Veterans affairs HDL-cholesterol intervention trial study group. N Engl J Med 1999; 314(6): 410–8CrossRefGoogle Scholar
  18. 18.
    Elkeles RS, Diamond JR, Poulter C, et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of Bezafibrate: the St Mary’s Ealing, Northwick Park diabetes cardiovascular disease prevention (SENDCAP) study. Diabetes Care 1998; 21(4): 641–8PubMedCrossRefGoogle Scholar
  19. 19.
    Frick MH, Heinonen OP, Huttunen JK, et al. Efficacy of gemfibrozil in dyslipidemic subjects with suspected heart disease: an ancillary study in the Helsinki heart study frame population. Ann Med 1993; 25(1): 41–5PubMedCrossRefGoogle Scholar
  20. 20.
    Jonkers IJAM, De Man FHAH, Onkenhout W, et al. Implication of fibrate therapy for homocysteine [abstract]. Lancet 1999; 354: 1208PubMedCrossRefGoogle Scholar
  21. 21.
    Watts GF, Dimmitt SB. Fibrates, dyslipoproteinemia and cardiovascular disease. Lipidology 1999; 10(6): 561–74CrossRefGoogle Scholar
  22. 22.
    Bucher HC, Griffith LE, Guyatt GH. Systematic review on risk and benefit of different cholesterol lowering interventions. Arterioscler Thromb Vasc Biol 1999; 19(2): 187–95PubMedCrossRefGoogle Scholar
  23. 23.
    Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian simvastatin survival study (4S). Lancet 1994; 344: 1383–9Google Scholar
  24. 24.
    Coronato A, Glass GB. Depression of intestinal uptake of radiovitamin B12 by cholestyramine. Proc Soc Exp Biol Med 1973; 142: 1341–4PubMedGoogle Scholar
  25. 25.
    Tonstad S, Refsum H, Ose L, et al. The C677T mutation in MHTFR gene predisposes to hyperhomocystenemia in children with familial hypercholestremia treated with cholestyramine. J Pediatr 1998; 132: 365–8PubMedCrossRefGoogle Scholar
  26. 26.
    Basu TK, Mann S. Vitamin B6 normalizes the altered sulphur aminoacid status of rats fed diets containing pharmacological concentration of niacin without reducing niacins hypolipidemic effect. J Nutr 1997; 127: 117–21PubMedGoogle Scholar
  27. 27.
    Munshi MN, Stone A, Fink L, et al. Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease. Metabolism 1996; 45: 133–5PubMedCrossRefGoogle Scholar
  28. 28.
    Baliga BS, Reynolds T, Fink LM, et al. Hyperhomocysteinemia in type 2 diabetes mellitus: cardiovascular risk factors and effect of treatment with folic acid and pyridoxine. Endocr Pract 2000; 6(6): 435–41PubMedGoogle Scholar
  29. 29.
    Effect of blood glucose control with metformin on complications in overweight patients with type 2 diabetes. UKPDS Group. Lancet 1998; 352: 854–65Google Scholar
  30. 30.
    Fontbonne A, Charles MA, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution: the biguanides and prevention of rRisks in obesity(BIGPRO) study group. Diabetes Care 1996; 19(9): 920–6PubMedCrossRefGoogle Scholar
  31. 31.
    Grant PJ. The effects of high and medium dose metformin therapy on cardiovascular risk factors in patients with type 2 diabetes: the diabetes and thrombosis research group. Diabetes Care 1996; 19(1): 64–6PubMedCrossRefGoogle Scholar
  32. 32.
    Palumbo PJ. Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus. J Diabet Complications 1998; 12(2): 110–9CrossRefGoogle Scholar
  33. 33.
    Carlsen SM, Foiling I, Grill V, et al. Metformin increases total serum homocysteine concentration in non-diabetic male patients with coronary artery disease. Scand J Clin Lab Invest 1997; 57: 521–8PubMedCrossRefGoogle Scholar
  34. 34.
    Bauman WA, Shaw S, Jayatilleke E, et al. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care 2000; 23(9): 1227–31PubMedCrossRefGoogle Scholar
  35. 35.
    Fonseca VA, Mudaliar S, Schmidt B, et al. Plasma homocysteine concentrations are regulated by acute hyperinsulinemia in non-diabetic but not type 2 diabetic subjects. Metabolism 1998; 47: 686–9PubMedCrossRefGoogle Scholar
  36. 36.
    Drzewoski J, Czupryniak L, Chwatko G, et al. Total homocysteine and insulin concentration in type 2 diabetic patients with secondary failure to oral agents. Diabetes Care 1999; 22(12): 2097–9PubMedCrossRefGoogle Scholar
  37. 37.
    Cronin CC, McPartlin JM, Barry DG, et al. Plasma homocysteine concentrations in patients with type 1 diabetes. Diabetes Care 1998; 21: 1843–7PubMedCrossRefGoogle Scholar
  38. 38.
    Hultberg B, Agardh CD, Agardh E, et al. Poor metabolic control, early age at onset, and marginal folate deficiency are associated with increasing concentration of plasma homocysteine in insulin dependant diabetes mellitus: a 5 year follow up study. Scan J Clin Lab Invest 1997; 57: 595–600CrossRefGoogle Scholar
  39. 39.
    Jacobs RL, House JD, Brosnan ME, et al. Effects of streptozotocin-induced diabetes and of insulin treatment on homocysteine metabolism in the rat. Diabetes 1998; 47: 1967–70PubMedCrossRefGoogle Scholar
  40. 40.
    Fonseca V, Dicker-Brown A, Ranganathan S, et al. Effects of a high fat-sucrose diet on enzymes in homocysteine metabolism in the rat. Metabolism 2000; 49(6): 736–41PubMedCrossRefGoogle Scholar
  41. 41.
    Andersson A, Hultberg B, Brattstrom L, et al. Decreased serum homocysteine in pregnancy. Eur J Clin Chem Biochem 1992; 30: 377–9Google Scholar
  42. 42.
    Wouters MG, Moorrees MT, van der Mooren MJ, et al. Plasma homocysteine and menopausal status. Eur J Clin Invest 1995; 25: 801–5PubMedCrossRefGoogle Scholar
  43. 43.
    Giltay EJ, Hoogeveen EK, Elbers JMH, et al. Effects of sex steroids on plasma total homocysteine concentration: a study in transsexual males and females. J Clin Endocrinol Metab 1998; 83(2): 550–3PubMedCrossRefGoogle Scholar
  44. 44.
    Barnabei VM, Phillips TM, Hsia J. Plasma homocysteine in women taking hormone replacement therapy: the postmenopausal estrogen/progestin interventions(PEPI) trial. J Womens Health Gend Based Med 1999; 8(9): 1167–72PubMedCrossRefGoogle Scholar
  45. 45.
    Hak AE, Polderman KH, Westendorp IC, et al. Increased plasma homocysteine after menopause. Atherosclerosis 2000; 149(1): 163–8PubMedCrossRefGoogle Scholar
  46. 46.
    Morris MS, Jacques PF, Selhub J, et al. Total homocysteine and estrogen status indicators in the third national health and nutrition examination survey. Am J Epidemiol 2000; 152(2): 140–8PubMedCrossRefGoogle Scholar
  47. 47.
    Berger PB, Herrmann RR, Dumensic DA. The effect of estrogen replacement therapy on total homocysteine in healthy postmenopausal women. Mayo Clin Proc 2000; 75(1): 18–23PubMedCrossRefGoogle Scholar
  48. 48.
    Green TJ, Houghton LA, Donovan U, et al. Oral contraceptives did not affect biochemical folate indexes and homocysteine concentrations in adolescent females. J Am Diet Assoc 1998; 98: 49–55PubMedCrossRefGoogle Scholar
  49. 49.
    Anker G, Lonning PE, Ueland PM, et al. Plasma concentration of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. Int J Cancer 1995; 60(3): 365–8PubMedCrossRefGoogle Scholar
  50. 50.
    Walsh BW, Paul S, Wild RA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized controlled trial. J Clin Endocrinol Meta 2000; 85(1): 214–8CrossRefGoogle Scholar
  51. 51.
    Zmunda JM, Bausserman LL, Maceroni D, et al. The effect of supraphysiologic doses of testosterone on fasting total homocysteine concentration in normal men. Atherosclerosis 1997; 130: 199–202CrossRefGoogle Scholar
  52. 52.
    Myllykangas-Luosujarvi R, Aho K, Kautiainen H, et al. Cardiovascular mortality in women with rheumatoid arthritis. J Rheumatol 1995; 22(6): 1007–8Google Scholar
  53. 53.
    Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with sero positive rheumatoid arthritis in northern Sweden. J Rheumatol 1997; 24(3): 445–51PubMedGoogle Scholar
  54. 54.
    Roubenoff R, Dellaripa P, Nadeau MR, et al. Abnormal homocysteine metabolism in rheumatoid arthritis. Arthritis Rheum 1997; 40(4): 718–22PubMedCrossRefGoogle Scholar
  55. 55.
    Haagsma CJ, Blom HJ, van Riel PLCM, et al. Influence of suphsalazine, methotrexate and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 1999; 58(2): 79–84PubMedCrossRefGoogle Scholar
  56. 56.
    Morgan SL, Baggott JE, Lee JY, et al. Folic acid supplementation prevents deficient blood folate concentration and hyper homocystenemia during long term, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol 1998; 25(3): 441–6PubMedGoogle Scholar
  57. 57.
    Ono H, Sakamoto A, Eguchi T, et al. Plasma total homocysteine concentrations in epileptic patients taking anti convulsants. Metabolism 1997; 46(8): 959–62PubMedCrossRefGoogle Scholar
  58. 58.
    Schwaninger M, Ringleb P, Winter R, et al. Elevated plasma concentrations of homocysteine in antiepileptic drug treatment. Epilepsia 1999; 40(3): 345–50PubMedCrossRefGoogle Scholar
  59. 59.
    Ueda K. Mechanism for reduction of folate by antiepileptic drugs during prolonged therapy. J Neurol Sci 1997; 145(1): 109–12PubMedCrossRefGoogle Scholar
  60. 60.
    Shorah CJ, Devitt H, Lucock M, et al. The responsiveness of plasma homocysteine to small increases in dietary folic acid: a primary care study. Eur J Clin Nutr 1998; 52: 407–11CrossRefGoogle Scholar
  61. 61.
    Ubbink JB. Vitamin status and hyperhomocystenemia in a healthy population. In: Graham I, Refsum H, Rosenberg I, et al., editors. Homocysteine metabolism: from basic science to clinical medicine. Boston (MA): Kluwer Academic Publishers, 1994Google Scholar
  62. 62.
    Franken DG, Boers GH, Blom HJ, et al. Treatment of mild hyperhomocystenemia in vascular disease patients. Arterioscler Thromb 1994; 14: 465–70PubMedCrossRefGoogle Scholar
  63. 63.
    Barber GW, Spaeth GL. Pyridoxine therapy in homocystinuria [letter]. Lancet 1967; I: 337CrossRefGoogle Scholar
  64. 64.
    Selhub J, Miller JW. The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosyl-methionine of the remethylation and transsulphuration of homocysteine. Am J Clin Nutr 1992; 55: 131–8PubMedGoogle Scholar
  65. 65.
    Lipsom MH, Kraus J, Rosenberg LD. Affinity of cystathionine beta-synthase for pyridoxal 5-phosphate in cultured cells: a mechanism for pyridoxine responsive homocystinuria. J Clin Invest 1980; 66: 188–93CrossRefGoogle Scholar
  66. 66.
    Van den Berg M, Boers GH, Franken DG, et al. Hyperhomocysteinemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995; 25: 176–81PubMedCrossRefGoogle Scholar
  67. 67.
    Brattstrom L, Israesson B, Norrving B, et al. Impaired homocysteine metabolism in early onset cerebral and peripheral occlusive arterial disease: effects of pyridoxine and folic acid treatment. Arthrosclerosis 1990; 81: 51–60CrossRefGoogle Scholar
  68. 68.
    Ubbink JB, Vermaak WJ, van der Merwe A, et al. Vitamin requirements for the treatment hyperhomocysteinemia in humans. J Nutr 1994; 124: 1927–33PubMedGoogle Scholar
  69. 69.
    Boers GHJ, van den Berg M, Franken DG. Treatment of mild hyperhomocysteinemia. In: Graham I, Refsum H, Rosenberg I, et al., editors. Homocysteine metabolism: from basic science to clinical medicine. Boston (MA): Kluwer Academic Publishers, 1994Google Scholar
  70. 70.
    van Gulener C, Janssen MJ, deMeer K, et al. Effect of folic acid and betaine on fasting and post methionine-loading plasma homocysteine and methionine concentration in chronic hemo-dialysis patients. J Intern Med 1999; 245(2): 175–83CrossRefGoogle Scholar
  71. 71.
    Woo KS, Chook P, Lolin Y, et al. Folic acid improves arterial endothelial function in adults with hyperhomocystenemia. J Am Coll Cardiol 1999; 34(7): 2002–6PubMedCrossRefGoogle Scholar
  72. 72.
    Chao CL, Chien KL, Lee YT. Effect of short term vitamin (folic Acid, vitamin B6 and B12) administration on endothelial dysfunction induced by post-methionine load hyperhomocysteinemia. Am J Cardiol 1999; 84(11): 1359–61PubMedCrossRefGoogle Scholar
  73. 73.
    Constans J, Blann AD, Resplandy F, et al. Three months supplementation of hyperhomocysteinemic patients with folic acid and vitamin B6 improves biological markers of endothelial dysfunction. Br J Haematol 1999; 107(4): 776–8PubMedCrossRefGoogle Scholar
  74. 74.
    Nappo F, De Rosa N, Marfella R, et al. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999; 281(22): 2113–8PubMedCrossRefGoogle Scholar
  75. 75.
    Vermeulen EG, Stehouwer CD, Twisk JW, et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomized, placebo-controlled trial. Lancet 2000; 355(9203): 517–22PubMedCrossRefGoogle Scholar
  76. 76.
    Van Guidener C, Janssen MJFM, Lambert J, et al. No change in impaired endothelial function after longterm folic acid therapy of hyperhomocysteinemia in haemodialysis patients. Nephro Dial Transplant 1998; 13: 106–12CrossRefGoogle Scholar
  77. 77.
    Undas A, Domagala TB, Jankowski M, et al. Treatment of hyperhomocysteinemia with folic acid and vitamins B12 and B6 attenuates thrombin generation. Thromb Res 1999; 95: 281–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Cyrus Desouza
    • 1
  • Maty Keebler
    • 1
  • Dennis B. McNamara
    • 1
  • Vivian Fonseca
    • 1
  1. 1.Tulane University School of MedicineNew OrleansUSA

Personalised recommendations